ABSTRACT
Introduction: Chronic respiratory diseases (CRDs) are growing problems worldwide. Pulmonary rehabilitation (PR) has proven benefits for patients with CRDs, but programmes need to be adapted to low resource settings, in the context of the recent COVID-19, to home-based delivery. Aim(s): To evaluate the feasibility of delivering home-based PR for patients with CRDs in Malaysia. Method(s): We recruited people with CRD from two hospitals in Klang Valley, Malaysia to home-based PR programme. Patients were provided education sessions, and assessments [functional exercise capacity {6-Minutes walking test (6MWT)}] and [Health-Related Quality of Life (HRQOL) {COPD Assessment Test (CAT)}] were made at centres prior to the start of programme. They performed exercise at least 5 sessions per week for 8 weeks at home and were supervised weekly via phone calls. Post PR, we assessed the attendance and retention rate and measured 6MWT and CAT at centre. Result(s): We recruited 30 patients. The retention rate was 93.3%;2 dropped out due to hospitalization. However, only 11(36.7%) attended post PR assessment at centres, of these 9 (81.8%) had performed all 40 sessions of home exercises. The attendance for post- PR assessment was limited due to COVD-19 restrictions that forbade travel in Malaysia at that time. Data from the 11 patients showed significant change in CAT scores, 5.09;pre: 22.45, post: 17.36(95% confidence interval (CI) 1.48, 8.70, p=0.01) but no significant change in 6MWT distance -24.36;pre: 276.36, post: 300.72(95% CI -80.52,-31.79, p=0.356). Conclusion(s): Home-based PR is feasible and can be a valuable method to deliver PR remotely.
ABSTRACT
SESSION TITLE: Medical Student/Resident Chest Infections Posters SESSION TYPE: Med Student/Res Case Rep Postr PRESENTED ON: October 18-21, 2020 INTRODUCTION: Sever coronavirus disease 2019 (COVID-19) represents viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leading to acute respiratory distress syndrome (ARDS). COVID-19 is a novel disease initially recognized in Wuhan, Hubei Province, China in December 2019 further declared as a global pandemic in January 2020. Along with other serious coronavirus infections, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome, that also cause ARDS, COVID-19 represents an ongoing global threat as this viral family has potential to mutate and infect nonimmune patients. Here we present a case of severe COVID-19 pneumonia leading to rapid ARDS requiring long hospital stay. CASE PRESENTATION: 47 years old male newly diagnosed with type 2 diabetes mellitus presented to the hospital in late March with five-day history of fever, chills, body aches, and dyspnea;only known exposure was working at a gas station. On admission he was febrile, tachycardic, and hypoxic requiring 4 liters via nasal canula, labs showed lymphopenia, elevated D-Dimer, LDH, CRP, ESR, and ferritin. Chest x-ray with bilateral multifocal airspace opacities (Figure 1). Admitted to the medical intensive care unit (MICU) for respiratory management, seven hours after admission he acutely decompensated requiring intubation, repeat chest x-ray showed worsening of bilateral opacities consistent with ARDS (figure 2). COVID-19 testing was positive the following day. Prone ventilation was initiated for 16 hours per day for a total of five days, with high PEEP, high FiO2, and tidal volumes 6ml/kg. Hospitalization complicated by acute kidney injury requiring continuous renal replacement therapy/intermittent hemodialysis and atrial fibrillation requiring amiodarone drip. He had prolonged mechanical ventilation and tracheotomy was delayed to high PEEP and hemodynamic lability but he had tracheotomy placement. Within one week of tracheostomy, he was weaned and placed on trach collar, discharged to nursing home to work with physical therapy and work towards getting back home to his family. DISCUSSION: COVID-19 pneumonia due to SARS-CoV-2 in general is an acute resolved disease with a mortality rate of 2%. However, severe disease might result in death due to massive alveolar hemorrhage such as in ARDS, progressive respiratory failure, and multiorgan failure. COVID-19 illness can be diagnosed by a consistent clinical history and positive SARS-CoV-2 testing. COVID-19 ARDS is diagnosed when COVID-19 positive patient meets the Berlin 2012 for ARDS. COVID-19 ARDS has worse outcomes compared to ARDS due to other causes, mortality can range from 65.7%-94% who received mechanical ventilation. There is ongoing research for treatment of COVID-19 ARDS. CONCLUSIONS: COVID-19 ARDS has worse outcomes when compared to ARDS due to other causes, there is on going research for treatment of COVID-19 related ARDS. Reference #1: Singhal T. (2020). A Review of Coronavirus Disease-2019 (COVID-19). Indian journal of pediatrics, 87(4), 281–286. Reference #2: Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., Tai, Y., Bai, C., Gao, T., Song, J., Xia, P., Dong, J., Zhao, J., & Wang, F. S. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet. Respiratory medicine, 8(4), 420–422. Reference #3: Gibson, P., Qin, L., Puah, S. (2020). COVID-19 ARDS: clinical features and differences to "usual” pre-COVID ARDS. The Medical Journal of Australia. DISCLOSURES: No relevant relationships by Hazim Bukamur, source=Web Response No relevant relationships by Kendall Creed, source=Web Response No relevant relationships by Jasmine Sekhon, source=Web Response No relevant relationships by Divya Vangipuram, source=Web Response